81 related articles for article (PubMed ID: 31576687)
21. Should We Abandon Intraperitoneal Chemotherapy in the Treatment of Advanced Ovarian Cancer? A Meta-Analysis.
Climent MT; Serra A; Balaguer C; Llueca A
J Pers Med; 2023 Nov; 13(12):. PubMed ID: 38138863
[TBL] [Abstract][Full Text] [Related]
22. A New Prognostic Instrument for Predicting the Probability of Completion of Cisplatin during Chemoradiation for Head and Neck Cancer.
Rades D; Zwaan I; Idel C; Pries R; Bruchhage KL; Hakim SG; Yu NY; Soror T
J Pers Med; 2023 Jul; 13(7):. PubMed ID: 37511733
[TBL] [Abstract][Full Text] [Related]
23. Cytoreductive Surgery (CRS) and HIPEC for Advanced Ovarian Cancer with Peritoneal Metastases: Italian PSM Oncoteam Evidence and Study Purposes.
Marrelli D; Ansaloni L; Federici O; Asero S; Carbone L; Marano L; Baiocchi G; Vaira M; Coccolini F; Di Giorgio A; Framarini M; Gelmini R; Palopoli C; Accarpio F; Fagotti A
Cancers (Basel); 2022 Dec; 14(23):. PubMed ID: 36497490
[TBL] [Abstract][Full Text] [Related]
24. Modified Intraperitoneal Chemotherapy Without Bevacizumab as a First-Line Therapy for Newly Diagnosed Advanced Epithelial Ovarian Cancer-Two Centers Experiences.
Shen Y; Tang S; Xu J; Xie X; Chen Z
Front Med (Lausanne); 2022; 9():846352. PubMed ID: 35372416
[TBL] [Abstract][Full Text] [Related]
25. A Modified Intraperitoneal Chemotherapy Regimen for Ovarian Cancer: Technique and Treatment Outcomes.
Kim JH; Ha HI; Kim MH; Han MR; Park SY; Lim MC
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638370
[TBL] [Abstract][Full Text] [Related]
26. A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (Review).
Falzone L; Scandurra G; Lombardo V; Gattuso G; Lavoro A; Distefano AB; Scibilia G; Scollo P
Int J Oncol; 2021 Jul; 59(1):. PubMed ID: 34132354
[TBL] [Abstract][Full Text] [Related]
27. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer.
Jaaback K; Johnson N; Lawrie TA
Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD005340. PubMed ID: 26755441
[TBL] [Abstract][Full Text] [Related]
28. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer.
Jaaback K; Johnson N; Lawrie TA
Cochrane Database Syst Rev; 2011 Nov; (11):CD005340. PubMed ID: 22071822
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of non-completion of intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer.
Chambers LM; Son J; Radeva M; DeBernardo R
J Gynecol Oncol; 2019 Nov; 30(6):e93. PubMed ID: 31576687
[TBL] [Abstract][Full Text] [Related]
30. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
Skaznik-Wikiel ME; Lesnock JL; McBee WC; Beriwal S; Zorn KK; Richard SD; Krivak TC; Edwards RP
Int J Gynecol Cancer; 2012 Feb; 22(2):232-7. PubMed ID: 22080886
[TBL] [Abstract][Full Text] [Related]
31. Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer.
Bixel K; Vetter M; Davidson B; Berchuck A; Cohn D; Copeland L; Fowler JM; Havrilesky L; Lee PS; O'Malley DM; Salani R; Valea F; Alvarez Secord A; Backes F
Gynecol Oncol; 2020 Mar; 156(3):530-534. PubMed ID: 31937450
[TBL] [Abstract][Full Text] [Related]
32. Disease Distribution at Presentation Impacts Benefit of IP Chemotherapy Among Patients with Advanced-Stage Ovarian Cancer.
Manning-Geist BL; Sullivan MW; Sarda V; Gockley AA; Del Carmen MG; Matulonis U; Growdon WB; Horowitz NS; Berkowitz RS; Clark RM; Worley MJ
Ann Surg Oncol; 2021 Oct; 28(11):6705-6713. PubMed ID: 33683525
[TBL] [Abstract][Full Text] [Related]
33. A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer.
Bouchard-Fortier G; Rosen B; Vyarvelska I; Pasetka M; Covens A; Gien LT; Kupets R; Pulman K; Ferguson SE; Vicus D
Gynecol Oncol; 2016 Jan; 140(1):36-41. PubMed ID: 26546964
[TBL] [Abstract][Full Text] [Related]
34. Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center.
Mueller JJ; Kelly A; Zhou Q; Iasonos A; Long Roche K; Sonoda Y; O'Cearbhaill RE; Zivanovic O; Chi DS; Gardner GJ
Gynecol Oncol; 2016 Dec; 143(3):496-503. PubMed ID: 27692668
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women.
Crim A; Rowland M; Ruskin R; Dvorak J; Greenwade M; Walter A; Gillen J; Ding K; Moore K; Gunderson C
Gynecol Oncol; 2017 Aug; 146(2):268-272. PubMed ID: 28583323
[TBL] [Abstract][Full Text] [Related]
36. Cancer Statistics, 2017.
Siegel RL; Miller KD; Jemal A
CA Cancer J Clin; 2017 Jan; 67(1):7-30. PubMed ID: 28055103
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
